Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a heterogeneous disorder that develops as a result of relatively inappropriate insulin secretion often in the setting of defective insulin action (insulin resistance). The factors responsible for insufficient insulin production in patients with type 2 diabetes are complex and are thought to involve a combination of genetic and metabolic defects, including chronic hyperglycemia, increased levels of free fatty acids, and dyslipidemia, which contribute to an inability to sustain adequate insulin secretion, defective β-cell proliferation, and/or increased β-cell apoptosis (1). Studies of the natural history of type 2 diabetes inform us that a progressive decline in β-cell function is common in diabetic patients independent of the method of treatment (2). Hence, new approaches are clearly needed that not only control metabolic abnormalities such as dyslipidemia and hyperglycemia, but that also preserve β-cell function and mass, perhaps by increasing the number of newly formed β-cells and/or decreasing β-cell death. Emerging experimental evidence has confirmed that elevated levels of glucose and specific monounsaturated fatty acids may be deleterious to β-cell survival in short-term studies of human islets (3). Although detailed information about the relative balance of β-cell proliferation and apoptosis in pancreases from subjects with type 2 diabetes is not available, recent autopsy data suggest that a combination of inappropriately decreased β-cell mass and increased β-cell apoptosis in the diabetic pancreas may be more common than previously appreciated (4, 5). Hence, absolute or relative deficiency of β-cells occurs paradoxically at a time when enhanced functional β-cell mass and increased insulin production is needed to overcome insulin resistance. Not surprisingly, the progressive deterioration in β-cell function that accompanies type 2 diabetes has sparked interest in identifying factors that either promote formation of new β-cells or inhibit the death of vulnerable β-cells (1). Experimental studies carried out predominantly in rodents have demonstrated that IGFs, hepatocyte growth factor, pituitary adenylate cyclase-activating polypeptide, PTHrP, epidermal growth factor receptor agonists in combination with gastrin, and incompletely characterized proteins such as islet neogenesis-associated protein, are capable of enhancing β-cell mass in the setting of experimental diabetes. Hence, prolonged administration of these agents may expand β-cell mass, ultimately leading to increased insulin secretion and improved glycemic control. Similarly, growth factors may also expand the number of human islet cells in experimental culture systems (6, 7). Nevertheless, none of these proteins has been demonstrated to rapidly lower blood glucose and improve metabolic control in preclinical models of diabetes independent of their chronic effects on islet proliferation or β-cell survival. Hence, pharmaceutical development of molecules exhibiting β-cell growth factor-like activity that do not concomitantly acutely lower blood glucose remains highly challenging as it may take weeks or more likely months to determine their potential efficacy in diabetic human subjects. New data presented in the article by Farilla et al. (8) in this issue of Endocrinology now demonstrate that glucagon-like peptide-1 (GLP-1), a gut hormone derived from enteroendocrine L cells, inhibits cell death in freshly isolated human islets cultured in vitro for 5 d. The antiapoptotic effects of GLP-1 have previously been demonstrated in diabetic rodents, islet cell lines, purified rat β-cells, and heterologous cells expressing the GLP-1 receptor (9–12). Intriguingly, GLP-1 receptor activation also enhances neuronal survival in diverse cellular and animal models of neuronal toxicity, and elimination of GLP-1 receptor function in mice is associated with increased neurotoxicity after peripheral administration of kainic acid (13, 14). Furthermore, the antiapoptotic actions of GLP-1 are essential for β-cell survival in response to cellular injury, as mice with a disruption of the GLP-1 receptor gene exhibit enhanced β-cell death and more severe hyperglycemia after exposure to streptozotocin (10). Farilla et al. (8) added GLP-1 (10 nm) to human islet cells isolated from three independent donors and observed preserved islet morphology in the GLP-1-treated islets, whereas control islets exhibited a greater degree of degradation and loss of three-dimensional structure. GLP-1 treatment was also associated with reduced morphological features of β-cell apoptosis (nuclear condensation and fragmentation) and decreased expression of active caspase-3, an enzyme that plays an essential role in the final pathway leading to programmed cell death. The authors found that GLP-1-treated islets exhibited a progressive increase in the levels of the prosurvival protein bcl-2, which likely contributed to the antiapoptotic actions of GLP-1 in the islet cultures. GLP-
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also promotes proliferation and reduces apoptosis of pancreatic β-cells, thereby maintaining their quality and functionality.130,218”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [218]
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“As GLP-1 treatment of human diabetic subjects improves metabolic control resulting in reduction of hyperglycemia and a decrease in circulating fatty acids (25), GLP-1 may also indirectly attenuate islet glucotoxicity and lipotoxicity, thereby resulting in healthier -cells and reduced -cell death (Fig.”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 3×
“glucose-dependent insulin secretion (8).”
BackgroundInfluentialSelective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 2×
“glycemia after exposure to streptozotocin (10).”
BackgroundSelf-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citation
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Rubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224726.61448.1b · Cited by 928
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Gastric Bypass for Obesity: Mechanisms of Weight Loss and Diabetes Resolution
Cummings, D. E., Overduin, J., & Foster-Schubert, K. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0433 · Cited by 503
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-12-01
- Volume
- 144
- Issue
- 12
- Pages
- 5145-5148
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2141880555
- Cited by
- 274
- References
- 39
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 12 · 2016: 10 · 2015: 6 · 2014: 10 · 2013: 18 · 2012: 7
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- glucagon-like peptide-1, beta-cell proliferation, beta-cell apoptosis, type 2 diabetes, beta-cell mass, islet neogenesis, insulin secretion, insulin resistance, growth factors, islet transplantation, beta-cell preservation, monounsaturated fatty acids, hyperglycemia, parathyroid hormone-related protein, gastrin
- MeSH terms
- Animals, Cell Division, Glucagon, Humans, Islets of Langerhans, Peptide Fragments, Protein Precursors, Apoptosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. https://app.cochat.ai/papers/10.1210/en.2003-1147
- The paper
- Drucker, D. J. (2003). Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. Endocrinology. https://doi.org/10.1210/en.2003-1147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.